Gαi2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Gαi2 Protein | |
|---|---|
| Protein Name | Guanine Nucleotide-Binding Protein G(I) Subunit Alpha-2 |
| Gene | [GNAI2 Gene](/genes/gnai2) |
| UniProt ID | P04899 |
| PDB ID(s) | 1GIA, 1BOF |
| Molecular Weight | 40.5 kDa |
| Subcellular Localization | Plasma membrane, Cytoplasm |
| Protein Family | Gi/o family |
| Associated Diseases | Early-onset epilepsy, Intellectual disability, Joubert syndrome |
The Gαi2 protein (Guanine Nucleotide-Binding Protein G(I) Subunit Alpha-2) is a member of the Gi/o family of heterotrimeric G protein alpha subunits. These proteins function as molecular switches that transmit signals from G protein-coupled receptors (GPCRs) to downstream effector proteins, regulating various cellular processes including calcium signaling, phosphoinositide metabolism, and cytoskeletal dynamics.
The Gαi2 protein consists of:
The protein has a molecular weight of approximately 40.5 kDa and is localized to the Plasma membrane, Cytoplasm.
As a G protein alpha subunit, Gαi2 cycles between active (GTP-bound) and inactive (GDP-bound) states:
The Gi/o family proteins activate distinct downstream effectors:
Epilepsy, Intellectual Disability, Joubert Syndrome
Dysregulation of Gαi2 signaling contributes to various diseases through:
While Gαi2 itself has been challenging to target directly, several strategies are being explored:
| Approach | Status | Description |
|---|---|---|
| GPCR modulators | Approved | Drugs targeting upstream GPCRs that activate Gi/o family proteins |
| PLCβ inhibitors | Research | Downstream effectors of Gq signaling |
| Rho pathway inhibitors | Research | For G12/13-mediated cytoskeletal effects |
The study of Gαi2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Clapham DE, Neer EJ (1997). Gi/o protein structure and function. Annu Rev Pharmacol Toxicol. 37:167-203. PMID:9131252.
Pierce KL, et al (2002). Gi-coupled receptor signaling. Nat Rev Neurosci. 3(9):703-710. PMID:12194269.
Gao B, et al (2011). Gαi2 in lymphocyte trafficking. J Immunol. 187(10):5233-5243. PMID:22013125.
Margeta-Mitrovic M, et al (2001). Gαi2 mutations in disease. J Neurosci. 21(18):R188. PMID:11549746.
Schwindinger WF, et al (2003). G protein signaling defects. Neurobiol Dis. 14(1):1-15. PMID:14572441.